MDM2 mRNA- MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST

摘要

This invention discloses a method for predicting the responsiveness of a cancer patient to treatment with an MDM2 antagonist of the formula I, II and III as disclosed herein, said method comprising administering at least MDM2 as a biomarker for predicting the response, Includes measuring mRNA expression levels of four gene panels including MDM2, XPC, BBC3 and CDKN2A.